Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.75 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.71 |
| ▸ | BUB1 | O43683 | 1/20 | 0.57 |
| ▸ | PRKACG | P22612 | 1/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.57 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.57 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404864 | 0.93 | MAPK14 (0.87) | MAPK14CYP2C9MAPK11HSPB1 | |
| SCHEMBL3093442 | 0.87 | MAPK14 (0.77) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL3407363 | 0.86 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL14326940 | 0.85 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL6744546 | 0.83 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11HSPB1 | |
| SCHEMBL5632201 | 0.83 | MAPK14 (0.79) | MAPK14CYP2C9MAPK11HSPB1 | |
| SCHEMBL14365176 | 0.83 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11HSPB1 | |
| SCHEMBL3411288 | 0.82 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11HSPB1 | |
| SCHEMBL3079711 | 0.82 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3424327 | 0.82 | MAPK14 (0.93) | MAPK14CYP2C9MAPK11HSPB1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1474395-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068747-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | MAPK14 4422/4885CYP2C9 1185/4885MAPK11 3834/4885 |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885MAPK11 27/4885 |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885MAPK11 27/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885MAPK11 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.